SCHEMBL970441

SCHEMBL970441

O=C(CN1CCc2c([nH]c3cc(F)ccc23)C1)N1CCN(C2CCC2)CC1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 5/20 0.52
ALDH1A1 P00352 3/20 0.47
KDM4E B2RXH2 1/20 0.47
HPGD P15428 1/20 0.47
GRIN2B Q13224 1/20 0.41
ADRA1A P35348 2/20 0.40
CTSK P43235 1/20 0.40
MMP1 P03956 1/20 0.40
MMP14 P50281 1/20 0.40
ADAMTS5 Q9UNA0 1/20 0.40
TRPV1 Q8NER1 2/20 0.39
HTR1A P08908 1/20 0.39
DRD2 P14416 1/20 0.39
ADRA1D P25100 1/20 0.39
ADRA1B P35368 1/20 0.39
CDK4 P11802 2/20 0.39
CCND1 P24385 2/20 0.39
USP2 O75604 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL970353 0.92 PARP1 (0.52) PARP1ALDH1A1KDM4EHPGDUSP2
SCHEMBL970324 0.86 ALDH1A1 (0.64) PARP1ALDH1A1KDM4EHPGDGRIN2B
SCHEMBL969089 0.85 PARP1 (0.65) PARP1ALDH1A1KDM4EHPGDGRIN2B
SCHEMBL967462 0.85 PARP1 (0.46) PARP1ALDH1A1KDM4EHPGD
SCHEMBL968434 0.84 ALDH1A1 (0.64) PARP1ALDH1A1KDM4EHPGDGRIN2B
SCHEMBL967934 0.84 PARP1 (0.48) PARP1ALDH1A1KDM4EHPGDGRIN2B
SCHEMBL967118 0.83 ALDH1A1 (0.63) PARP1ALDH1A1KDM4EHPGDGRIN2B
SCHEMBL967959 0.83 USP2 (0.54) PARP1ALDH1A1KDM4EHPGDUSP2
SCHEMBL967791 0.83 NPC1 (0.58) PARP1ALDH1A1KDM4EHPGDGRIN2B
SCHEMBL13985808 0.83 PARP1 (0.52) PARP1ALDH1A1KDM4EHPGDGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US claimed
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
WO-2009003003-A2 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2008-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES HRH3, HRH4, HRH1 PARP1 2898/4885ALDH1A1 812/4885KDM4E 3037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.